Q1 Earnings Forecast for ANIK Issued By Barrington Research

Anika Therapeutics, Inc. (NASDAQ:ANIK) – Barrington Research issued their Q1 2026 earnings estimates for shares of Anika Therapeutics in a research report issued on Thursday, March 13th. Barrington Research analyst M. Petusky expects that the biotechnology company will earn ($0.16) per share for the quarter. Barrington Research has a “Outperform” rating and a $20.00 price target on the stock. The consensus estimate for Anika Therapeutics’ current full-year earnings is ($0.84) per share. Barrington Research also issued estimates for Anika Therapeutics’ Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS and FY2027 earnings at ($0.45) EPS.

Separately, StockNews.com raised shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday.

Anika Therapeutics Stock Performance

NASDAQ:ANIK opened at $15.91 on Monday. The firm’s fifty day moving average is $16.90 and its 200-day moving average is $19.47. Anika Therapeutics has a 52 week low of $14.95 and a 52 week high of $29.11. The firm has a market cap of $233.02 million, a P/E ratio of -2.39 and a beta of 0.95.

Anika Therapeutics (NASDAQ:ANIK) last posted its earnings results on Wednesday, March 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.13). Anika Therapeutics had a negative return on equity of 2.22% and a negative net margin of 59.40%. The business had revenue of $30.60 million for the quarter, compared to the consensus estimate of $29.00 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Atria Investments Inc acquired a new position in Anika Therapeutics during the third quarter worth $218,000. Cornercap Investment Counsel Inc. acquired a new position in Anika Therapeutics during the third quarter worth $238,000. Quest Partners LLC raised its holdings in Anika Therapeutics by 115.8% during the third quarter. Quest Partners LLC now owns 6,904 shares of the biotechnology company’s stock worth $171,000 after buying an additional 3,705 shares during the last quarter. Segall Bryant & Hamill LLC raised its holdings in Anika Therapeutics by 1.7% during the third quarter. Segall Bryant & Hamill LLC now owns 108,799 shares of the biotechnology company’s stock worth $2,687,000 after buying an additional 1,794 shares during the last quarter. Finally, FMR LLC raised its holdings in Anika Therapeutics by 25.3% during the third quarter. FMR LLC now owns 24,721 shares of the biotechnology company’s stock worth $611,000 after buying an additional 4,996 shares during the last quarter. 91.53% of the stock is owned by institutional investors.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.